These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 23627786)

  • 21. The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): an evidence-based review.
    Parrott AC
    Psychopharmacology (Berl); 2007 Apr; 191(2):181-93. PubMed ID: 17297639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
    Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
    J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [MDMA ("Ecstasy")--a dangerous drug or psychotherapeutic drug?].
    Szukaj M
    Nervenarzt; 1994 Nov; 65(11):802-5. PubMed ID: 7816160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How MDMA's pharmacology and pharmacokinetics drive desired effects and harms.
    Michael White C
    J Clin Pharmacol; 2014 Mar; 54(3):245-52. PubMed ID: 24431106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?
    Feduccia AA; Mithoefer MC
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jun; 84(Pt A):221-228. PubMed ID: 29524515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ecstasy: as harmful as heroin?
    Scott R
    J Law Med; 2009 Dec; 17(3):327-48. PubMed ID: 20169795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients.
    Schifano F; Di Furia L; Forza G; Minicuci N; Bricolo R
    Drug Alcohol Depend; 1998 Sep; 52(1):85-90. PubMed ID: 9788011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance.
    Parrott AC; Lasky J
    Psychopharmacology (Berl); 1998 Oct; 139(3):261-8. PubMed ID: 9784083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale.
    Johansen PØ; Krebs TS
    J Psychopharmacol; 2009 Jun; 23(4):389-91. PubMed ID: 19273493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?
    Gouzoulis-Mayfrank E; Daumann J
    Addiction; 2006 Mar; 101(3):348-61. PubMed ID: 16499508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The potential use of N-methyl-3,4-methylenedioxyamphetamine (MDMA) assisted psychotherapy in the treatment of eating disorders comorbid with PTSD.
    Brewerton TD; Lafrance A; Mithoefer MC
    Med Hypotheses; 2021 Jan; 146():110367. PubMed ID: 33203569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contribution of Impulsivity and Serotonin Receptor Neuroadaptations to the Development of an MDMA ('Ecstasy') Substance Use Disorder.
    Schenk S; Aronsen D
    Curr Top Behav Neurosci; 2017; 34():17-32. PubMed ID: 26718587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MDMA ('ecstasy') and other 'club drugs'. The new epidemic.
    Koesters SC; Rogers PD; Rajasingham CR
    Pediatr Clin North Am; 2002 Apr; 49(2):415-33. PubMed ID: 11993291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis.
    Smith KW; Sicignano DJ; Hernandez AV; White CM
    J Clin Pharmacol; 2022 Apr; 62(4):463-471. PubMed ID: 34708874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurocognitive function in users of MDMA: the importance of clinically significant patterns of use.
    Hanson KL; Luciana M
    Psychol Med; 2004 Feb; 34(2):229-46. PubMed ID: 14982129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review of potential psychedelic treatments for PTSD.
    Henner RL; Keshavan MS; Hill KP
    J Neurol Sci; 2022 Aug; 439():120302. PubMed ID: 35700643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurocognitive impairments in MDMA and other drug users: MDMA alone may not be a cognitive risk factor.
    Hanson KL; Luciana M
    J Clin Exp Neuropsychol; 2010 Apr; 32(4):337-49. PubMed ID: 20397296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychedelic drugs: the ups and downs of ecstasy.
    Check E
    Nature; 2004 May; 429(6988):126-8. PubMed ID: 15141183
    [No Abstract]   [Full Text] [Related]  

  • 39. Ethanol, 3,4-methylenedioxymethamphetamine (ecstasy) and their combination: long-term behavioral, neurochemical and neuropharmacological effects in the rat.
    Cassel JC; Riegert C; Rutz S; Koenig J; Rothmaier K; Cosquer B; Lazarus C; Birthelmer A; Jeltsch H; Jones BC; Jackisch R
    Neuropsychopharmacology; 2005 Oct; 30(10):1870-82. PubMed ID: 15785779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].
    Majić T; Jungaberle H; Schmidt TT; Zeuch A; Hermle L; Gallinat J
    Fortschr Neurol Psychiatr; 2017 Jul; 85(7):383-392. PubMed ID: 28768346
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.